Cobenfy: A Revolutionary Breakthrough in Schizophrenia Treatment

Cobenfy: A Revolutionary Breakthrough in Schizophrenia Treatment On December 3, 2024, the landscape of schizophrenia treatment witnessed a monumental shift with the FDA approval of Cobenfy, a novel medication combining xanomeline and trospium chloride. This marks the first major advancement in antipsychotic drugs since the establishment of traditional dopamine-receptor-targeting medications as the standard of care. […]

High Doses of ADHD Drugs and Their Link to Psychosis: An In-Depth Analysis

High Doses of ADHD Drugs and Their Link to Psychosis: An In-Depth Analysis Attention Deficit Hyperactivity Disorder (ADHD) is a condition that affects millions of people worldwide, leading to difficulties in maintaining attention, controlling impulses, and regulating activity levels. One of the most commonly prescribed treatments for ADHD is Adderall, a stimulant medication that has […]

New Insights Could Help Prevent Psychosis Relapses in Youth and Young Adults

New Insights Could Help Prevent Psychosis Relapses in Youth and Young Adults Recent findings from researchers at McGill University are shedding new light on the understanding of delusions in youth and young adults, particularly those undergoing early intervention treatment for psychosis. Delusions, which are strong beliefs that do not align with commonly accepted reality, are […]